-1.6 C
New York
Friday, March 1, 2024

Wall Street analysts are cautiously optimistic on J&J’s ‘one-dose’ Covid vaccine

  • Johnson & Johnson is expected to deliver preliminary late-stage trial results for its one-dose Covid vaccine candidate by the end of January.
  • If its jab is proven to be safe and effective, the company aims to deliver at least 1 billion doses by the end of the year. 

Johnson & Johnson Coronavirus vaccine illustrationDado Ruvic | Reuters

LONDON — Health care systems around the world are struggling to cope with rising numbers of Covid-19 infections as they race against the clock to vaccinate the vulnerable. 

The three vaccines currently approved for use by major Western economies all require two separate jabs and given supplies are limited, governments are considering contentious tactics like stretching the length of time between doses to get at least one dose to as many people as possible. 

A one-shot vaccine could significantly improve our ability to fight the virus — and we may have one soon.

J&J's late-stage trial 

Johnson & Johnson is expected to deliver preliminary late-stage trial results for its one-dose Covid vaccine candidate by the end of January. If its jab is proven to be safe and effective, the company aims to deliver at least 1 billion doses by the end of the year. 

Related Articles

Latest Articles